Current studies of liposome muramyl tripeptide (CGP 19835a lipid) therapy for metastasis in spontaneous tumors

A progress review

E. G. Macewen, I. D. Kurzman, S. Helfand, D. Vail, C. London, W. Kisseberth, R. C. Rosenthal, L. E. Fox, E. T. Keller, J. Obradovich, B. Madewell, C. Rodriguez, B. Kitchell, J. Fidel, S. Susaneck, M. Rosenberg

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Targeted delivery of macrophage activating agents is an attractive approach to treat micrometastatic disease. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) is a potent activator of monocytes/macrophages in humans, mice, and dogs. We have conducted clinical trials in dogs with malignant and highly metastatic spontaneous tumors. Presented are results of our trials evaluating L-MTP-PE in combination with surgery and chemotherapy in dogs with spontaneous osteosarcoma and hemangiosarcoma, particularly relevant malignancies having many similarities to human cancer. Osteosarcoma dogs received chemotherapy following surgery (cisplatin q 28 days × 4). At completion of chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.021). Dogs with splenic hemangiosarcoma received combination chemotherapy following surgery (doxorubicin and cyclophosphamide q 21 days × 4). At the first chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.03). These studies show that L-MTP-PE is an effective agent for treatment of metastasis and can be safely administered in combination with chemotherapy.

Original languageEnglish (US)
Pages (from-to)391-396
Number of pages6
JournalJournal of Drug Targeting
Volume2
Issue number5
DOIs
StatePublished - 1994

Fingerprint

Liposomes
Dogs
Neoplasm Metastasis
Lipids
Placebos
Neoplasms
Drug Therapy
Hemangiosarcoma
Osteosarcoma
Combination Drug Therapy
Therapeutics
Macrophages
Survival
mifamurtide
Doxorubicin
Cyclophosphamide
Cisplatin
Monocytes
Clinical Trials

Keywords

  • Canine
  • Hemangiosarcoma
  • Immunotherapy
  • Liposome
  • Muramyl tripeptide
  • Osteosarcoma

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Current studies of liposome muramyl tripeptide (CGP 19835a lipid) therapy for metastasis in spontaneous tumors : A progress review. / Macewen, E. G.; Kurzman, I. D.; Helfand, S.; Vail, D.; London, C.; Kisseberth, W.; Rosenthal, R. C.; Fox, L. E.; Keller, E. T.; Obradovich, J.; Madewell, B.; Rodriguez, C.; Kitchell, B.; Fidel, J.; Susaneck, S.; Rosenberg, M.

In: Journal of Drug Targeting, Vol. 2, No. 5, 1994, p. 391-396.

Research output: Contribution to journalArticle

Macewen, EG, Kurzman, ID, Helfand, S, Vail, D, London, C, Kisseberth, W, Rosenthal, RC, Fox, LE, Keller, ET, Obradovich, J, Madewell, B, Rodriguez, C, Kitchell, B, Fidel, J, Susaneck, S & Rosenberg, M 1994, 'Current studies of liposome muramyl tripeptide (CGP 19835a lipid) therapy for metastasis in spontaneous tumors: A progress review', Journal of Drug Targeting, vol. 2, no. 5, pp. 391-396. https://doi.org/10.3109/10611869408996814
Macewen, E. G. ; Kurzman, I. D. ; Helfand, S. ; Vail, D. ; London, C. ; Kisseberth, W. ; Rosenthal, R. C. ; Fox, L. E. ; Keller, E. T. ; Obradovich, J. ; Madewell, B. ; Rodriguez, C. ; Kitchell, B. ; Fidel, J. ; Susaneck, S. ; Rosenberg, M. / Current studies of liposome muramyl tripeptide (CGP 19835a lipid) therapy for metastasis in spontaneous tumors : A progress review. In: Journal of Drug Targeting. 1994 ; Vol. 2, No. 5. pp. 391-396.
@article{f529fe72dcb0439cb98b51fa489f560f,
title = "Current studies of liposome muramyl tripeptide (CGP 19835a lipid) therapy for metastasis in spontaneous tumors: A progress review",
abstract = "Targeted delivery of macrophage activating agents is an attractive approach to treat micrometastatic disease. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) is a potent activator of monocytes/macrophages in humans, mice, and dogs. We have conducted clinical trials in dogs with malignant and highly metastatic spontaneous tumors. Presented are results of our trials evaluating L-MTP-PE in combination with surgery and chemotherapy in dogs with spontaneous osteosarcoma and hemangiosarcoma, particularly relevant malignancies having many similarities to human cancer. Osteosarcoma dogs received chemotherapy following surgery (cisplatin q 28 days × 4). At completion of chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.021). Dogs with splenic hemangiosarcoma received combination chemotherapy following surgery (doxorubicin and cyclophosphamide q 21 days × 4). At the first chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.03). These studies show that L-MTP-PE is an effective agent for treatment of metastasis and can be safely administered in combination with chemotherapy.",
keywords = "Canine, Hemangiosarcoma, Immunotherapy, Liposome, Muramyl tripeptide, Osteosarcoma",
author = "Macewen, {E. G.} and Kurzman, {I. D.} and S. Helfand and D. Vail and C. London and W. Kisseberth and Rosenthal, {R. C.} and Fox, {L. E.} and Keller, {E. T.} and J. Obradovich and B. Madewell and C. Rodriguez and B. Kitchell and J. Fidel and S. Susaneck and M. Rosenberg",
year = "1994",
doi = "10.3109/10611869408996814",
language = "English (US)",
volume = "2",
pages = "391--396",
journal = "Journal of Drug Targeting",
issn = "1061-186X",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Current studies of liposome muramyl tripeptide (CGP 19835a lipid) therapy for metastasis in spontaneous tumors

T2 - A progress review

AU - Macewen, E. G.

AU - Kurzman, I. D.

AU - Helfand, S.

AU - Vail, D.

AU - London, C.

AU - Kisseberth, W.

AU - Rosenthal, R. C.

AU - Fox, L. E.

AU - Keller, E. T.

AU - Obradovich, J.

AU - Madewell, B.

AU - Rodriguez, C.

AU - Kitchell, B.

AU - Fidel, J.

AU - Susaneck, S.

AU - Rosenberg, M.

PY - 1994

Y1 - 1994

N2 - Targeted delivery of macrophage activating agents is an attractive approach to treat micrometastatic disease. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) is a potent activator of monocytes/macrophages in humans, mice, and dogs. We have conducted clinical trials in dogs with malignant and highly metastatic spontaneous tumors. Presented are results of our trials evaluating L-MTP-PE in combination with surgery and chemotherapy in dogs with spontaneous osteosarcoma and hemangiosarcoma, particularly relevant malignancies having many similarities to human cancer. Osteosarcoma dogs received chemotherapy following surgery (cisplatin q 28 days × 4). At completion of chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.021). Dogs with splenic hemangiosarcoma received combination chemotherapy following surgery (doxorubicin and cyclophosphamide q 21 days × 4). At the first chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.03). These studies show that L-MTP-PE is an effective agent for treatment of metastasis and can be safely administered in combination with chemotherapy.

AB - Targeted delivery of macrophage activating agents is an attractive approach to treat micrometastatic disease. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) is a potent activator of monocytes/macrophages in humans, mice, and dogs. We have conducted clinical trials in dogs with malignant and highly metastatic spontaneous tumors. Presented are results of our trials evaluating L-MTP-PE in combination with surgery and chemotherapy in dogs with spontaneous osteosarcoma and hemangiosarcoma, particularly relevant malignancies having many similarities to human cancer. Osteosarcoma dogs received chemotherapy following surgery (cisplatin q 28 days × 4). At completion of chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.021). Dogs with splenic hemangiosarcoma received combination chemotherapy following surgery (doxorubicin and cyclophosphamide q 21 days × 4). At the first chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.03). These studies show that L-MTP-PE is an effective agent for treatment of metastasis and can be safely administered in combination with chemotherapy.

KW - Canine

KW - Hemangiosarcoma

KW - Immunotherapy

KW - Liposome

KW - Muramyl tripeptide

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=20244387692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244387692&partnerID=8YFLogxK

U2 - 10.3109/10611869408996814

DO - 10.3109/10611869408996814

M3 - Article

VL - 2

SP - 391

EP - 396

JO - Journal of Drug Targeting

JF - Journal of Drug Targeting

SN - 1061-186X

IS - 5

ER -